In this article, we will look at the 10 Fastest Growing Tech Penny Stocks to Buy.

Tech penny stocks sit at the speculative end of the market, but they are getting more attention as investors look below mega-cap software and semiconductor names for faster revenue growth. The group can include AI infrastructure suppliers, digital platforms, electronics, communications equipment, and biotechnology companies whose value is driven by proprietary scientific platforms rather than conventional healthcare delivery.

Royce Investment Partners says “micro-cap stocks are leading the market” and notes that its investable universe includes “many companies selling into the AI supply chain,” including firms providing the “picks and shovels for the AI revolution.” Fidelity also supports the broader technology spending backdrop, saying it sees “no prospect of flagging AI spending” and expects “graphics processing units, high-speed memory and data centers” to remain important in 2026 and beyond. It also points to other technology themes such as “cloud computing, digital transformation, and digital security.” For the biotech names in a broad tech screen, Janus Henderson gives the clearest bridge, saying biotechnology sits at the frontier of “therapeutics innovation,” where “AI, genomics, and molecular engineering” are “accelerating the pace of discovery.”

Against this backdrop, fast-growing tech penny stocks are not just about low-priced speculation. Some companies are tied to real technology platforms, applied science, and infrastructure demand. With that in mind, let’s take a look at the 10 Fastest Growing Tech Penny Stocks to Buy.

Our Methodology

We used the Finviz screener to identify tech stocks that are trading below $5 per share and have posted compounded annual revenue growth of over 50% in the past 3 years. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.

Note: Some companies below are not pure-play tech stocks. Even so, they maintain a notable presence in the technology space through various aspects of their business.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10. PowerFleet, Inc. (NASDAQ:AIOT)

On July 1, 2026, PowerFleet, Inc. (NASDAQ:AIOT) announced the Australian launch of SafeGuard, an AI-powered risk intelligence solution for on-road driver behavior. Available as an add-on to Powerfleet’s VisionAI video solution and integrated within the Unity platform, SafeGuard uses artificial intelligence to assess driver risk across a fleet and help safety teams focus on events and behaviors most likely to lead to incidents. Brodie von Berg, Managing Director, Powerfleet APAC, said SafeGuard helps teams identify the “highest-risk drivers and behaviours” in real time, supporting earlier intervention and coaching.

Powerfleet said SafeGuard combines real-time risk monitoring, AI-powered driving risk analysis, intelligent video event review, and live intervention capabilities. Operators using SafeGuard have reported up to 83% reduction in on-road risk, 95% fewer false positive video event alerts, and an 80% reduction in video review time.

Also on July 1, PowerFleet announced that its Board of Directors approved a stock repurchase program authorizing the company to repurchase up to $30M of common stock over the next 24 months. On June 16, Raymond James lowered the firm’s price target on PowerFleet to $7 from $8 and kept an Outperform rating on the shares. Raymond James said Q4 results came in ahead of expectations, with an improved FY27 outlook reflecting accelerating growth and profitability into year-end.

PowerFleet, Inc. (NASDAQ:AIOT) provides artificial intelligence-of-things solutions for managing high-value enterprise and mid-market assets in North America, Israel, Africa, Europe, the Middle East, Australia, and internationally.

9. Geron Corporation (NASDAQ:GERN)

On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material to the employees’ acceptance of employment with Geron.

The stock options have an exercise price of $1.23 per share, equal to the closing price of Geron’s common stock on the grant date. The options have a ten-year term and vest over four years, with 12.5% of the shares underlying the options vesting on the six-month anniversary of the employee’s employment commencement and the remaining shares vesting over the following 42 months in equal installments, subject to continued employment.

Earlier in June, Geron Corporation (NASDAQ:GERN) announced that members of its management team were scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.

Geron Corporation (NASDAQ:GERN) focuses on the development of therapeutic products for oncology.

8. Nano Dimension Ltd. (NASDAQ:NNDM)

On June 16, 2026, Nano Dimension Ltd. (NASDAQ:NNDM) and Infinite Epigenetics issued a shareholder update on the proposed business combination announced on June 15. Nano said it reviewed Murchinson’s recent letter on the proposed transaction and noted that final transaction details were still being negotiated. The company said it would provide complete details and a description of the proposed transaction once finalized.

Nano said Infinite Epigenetics is “not a concept company” and “not an AI wrapper,” pointing to operating businesses, a CLIA-certified methylation laboratory, existing commercial revenue, a network of more than 7,500 healthcare providers, issued intellectual property, and a proprietary database of more than 120,000 biological samples. The company also said Infinite’s team has authored over 50 publications, and that a single sample processed in Infinite’s CLIA-certified laboratory can read more than one million epigenetic signals. Nano said it selected Infinite from approximately 20 opportunities it evaluated and framed the transaction as a shift from 3D printing to AI-powered preventive health and diagnostics.

Nano said the term sheet with Infinite followed a months-long review process with support from financial and legal advisors, as well as consultants assessing Infinite’s technology, target markets, and operations. The company said the proposed combination values Nano at net cash plus a 20% premium, preserves the value of Nano’s Nasdaq listing, allows holders to retain contingent value rights on Nano’s legacy assets, and adds equity upside. Nano also said the contemplated transaction would not provide separate or transaction-driven compensation or payouts and that any definitive agreement would be subject to a shareholder vote.

Nano Dimension Ltd. (NASDAQ:NNDM) provides industrial manufacturing solutions for design-to-manufacturing of electronics and mechanical parts in the Americas, the Asia Pacific, Europe, the Middle East, and Africa.

7. Century Therapeutics, Inc. (NASDAQ:IPSC)

On July 9, 2026, Century Therapeutics, Inc. (NASDAQ:IPSC) announced that its abstracts were accepted for oral presentations at two upcoming scientific congresses. Both presentations will highlight CNTY-813, Century’s iPSC-derived islet replacement therapy program engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes.

The presentations are scheduled for the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28-October 2, 2026 in Milan, Italy, and the Breakthrough T1D Clinical & Research Congress 2026, taking place October 9-11, 2026 in Philadelphia, Pennsylvania. Century said CNTY-813 is designed to enable durable engraftment without chronic systemic immunosuppression, and the company is targeting an IND submission in the fourth quarter of 2026.

On June 9, Century Therapeutics announced new preclinical data for CNTY-813 at the American Diabetes Association Scientific Sessions. In preclinical models, the therapy demonstrated durable glucose control for over eight months and maintained insulin secretion under allogeneic immune pressure without immunosuppression. CEO Brent Pfeiffenberger said the data advance the company’s case for a “potentially functional cure” for type 1 diabetes, while noting that the IND submission remains on track for the fourth quarter of 2026 and initial clinical data are anticipated in the second half of 2027.

Century Therapeutics, Inc. (NASDAQ:IPSC) develops allogeneic cell therapies for the treatment of solid tumors, hematological malignancies, and autoimmune diseases.

6. TON Strategy Co (NASDAQ:TONX)

On July 1, 2026, TON Strategy Co (NASDAQ:TONX) announced that it entered into a Rule 10b5-1 trading plan to facilitate the repurchase of common stock during a two-month period beginning July 1. The plan was established under the company’s existing $250M stock repurchase authorization announced on September 3, 2025. Virtu Financial will serve as the executing broker under the plan.

On June 15, TON Strategy highlighted the TON community’s rebrand of Toncoin, the native currency of The Open Network, to “Gram.” The rebrand followed a community governance vote that concluded on June 8, 2026, with public reports indicating that 81.22% of participating voting power supported the proposal. TON Strategy said the rebrand changes the native asset ticker, while the underlying blockchain and network name remain TON. No token swap, migration, bridge, claim, or conversion is required, and TON Strategy’s Nasdaq ticker, TONX, is unchanged.

CEO Kevin Wilson called the move from Toncoin to Gram an “important identity milestone” for the TON ecosystem, saying the new name can help make the network easier for users to understand as TON develops around Telegram-native use cases. The company also said recent TON ecosystem developments have focused on improving usability, performance, and developer experience.

TON Strategy Co (NASDAQ:TONX) operates as an interactive video-based social commerce company.

5. Gloo Holdings, Inc. (NASDAQ:GLOO)

On July 9, 2026, Gloo Holdings, Inc. (NASDAQ:GLOO) priced a 7M share secondary at $3.25. The deal is priced below the last closing price of $3.98. JPMorgan is acting as the sole book-running manager for the offering.

On June 9, Benchmark raised the firm’s price target on Gloo to $15 from $14 and kept a Buy rating on the shares after “yet another beat and raise” in fiscal Q1. Benchmark called Gloo “an unchallenged leader” in the faith and flourishing space and continued to view the stock as one of the more compelling risk/reward opportunities in its coverage.

Also on June 9, Gloo reported Q1 EPS of (21c), compared with estimates of (18c), and revenue of $41.5M, compared with consensus of $36.0M. CEO Scott Beck said AI remains a “force multiplier” behind the company’s platform and said the quarter exceeded guidance and analyst consensus.

Gloo Holdings, Inc. (NASDAQ:GLOO) designs and develops a vertical technology platform for the faith and flourishing ecosystem.

4. Autolus Therapeutics plc (NASDAQ:AUTL)

On July 1, 2026, Autolus Therapeutics plc (NASDAQ:AUTL) announced that the Compensation Committee of its Board of Directors granted stock option awards to purchase an aggregate of 25,420 American Depositary Shares and 87,530 restricted stock units to 13 employees under the company’s 2025 Inducement Plan. The awards were granted as inducement material to the individuals becoming employees of Autolus in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option awards and RSUs have a grant date of June 24, 2026. The stock options have an exercise price of $1.66 per share, equal to the closing price of Autolus’ common stock on June 23, 2026. Each stock option award has a ten-year term and vests over four years, while each RSU vests in four equal annual installments, subject to continued service through the applicable vesting dates.

Over a month ago, H.C. Wainwright raised the firm’s price target on Autolus Therapeutics to $10 from $9 and kept a Buy rating on the shares after the Q1 report. H.C. Wainwright said the company’s Aucatyzl U.S. demand is growing, while the UK launch is off to a positive start.

Autolus Therapeutics plc (NASDAQ:AUTL) develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally.

3. Ovid Therapeutics Inc. (NASDAQ:OVID)

On July 8, 2026, Ovid Therapeutics Inc. (NASDAQ:OVID) announced several strategic appointments. Kevin Norrett will join Ovid as chief business officer to lead business and corporate development functions, as well as strategic partnerships. Most recently, Norrett served as chief business officer at Soleno Therapeutics.

Ovid also promoted Charles Carter to CFO, where Carter will lead business and financial operations. Carter succeeds Jeffrey Rona, who will remain a long-term advisor to the company through 2027. Victoria Fort was promoted to chief strategy officer, leading enterprise strategy, investor relations, and operational growth initiatives.

In May, Ovid Therapeutics reported Q1 EPS of (12c), compared with the consensus of (11c). CEO Meg Alexander said the first quarter reflected “focused execution” and continued progress across the company’s pipeline of small molecule medicines for intractable brain conditions. Alexander said development programs remain on track, the clinical organization has expanded, and the company expects to be well capitalized into 2029.

Ovid Therapeutics Inc. (NASDAQ:OVID) develops small-molecule medicines for brain disorders, including epilepsies and seizure-related neurological disorders in the United States.

2. Cibus, Inc. (NASDAQ:CBUS)

On June 17, 2026, Cibus, Inc. (NASDAQ:CBUS) welcomed a landmark European Union decision under which crops improved without adding foreign DNA will be treated like conventionally bred crops rather than transgenic GMOs. Cibus said the decision opens a path for European farmers to grow cleaner crops more productively, including by fighting disease and pests with fewer chemicals.

Cibus said the new rules draw a line between transgenic GMOs, which add foreign DNA, and the precise, non-transgenic improvements Cibus makes to a plant’s own genes. The company said crops that resist disease, use water and nutrients more efficiently, and require fewer chemicals qualify for the framework’s non-GMO fast lane, where they are treated the same as conventionally bred crops. President and COO Peter Beetham said the E.U. completed a “science-based review” and recognized that crops with changes that could occur in nature or through traditional breeding should be regulated accordingly.

On June 9, Cibus announced leadership changes under its previously announced succession planning strategy. Craig Wichner, a board member since November 2025, was appointed CEO. Peter Beetham, who served as Interim CEO, will continue as President and COO. Wichner and Beetham also resigned from the Cibus Board of Directors as part of the reorganization and plan.

Cibus, Inc. (NASDAQ:CBUS) is an agricultural biotechnology company that develops and licenses gene-edited plant traits.

1. Datavault AI Inc. (NASDAQ:DVLT)

On July 9, 2026, Datavault AI Inc. (NASDAQ:DVLT) signed a three-party joint venture agreement with Unity Reserve and Mandela Dlamini, or MDM LLC, forming Mandela Digital. The venture is developing the Mandela Dollar, or MUSD, a proposed 1:1 USD-backed stablecoin designed to advance financial inclusion across the Global South and beyond. Under the agreement, Datavault AI becomes Mandela Digital’s founding and exclusive technology partner, deploying its full technology stack to power the venture.

Also on July 9, Datavault AI announced that the United States Patent and Trademark Office issued a Notice of Allowance, dated July 1, for U.S. Patent Application No. 19/445,241, “Method and System for Mitigating Naked and Excessive Short Selling through Tokenized Dividend Distribution.” The notice allowed all 24 pending claims. The company said the application was filed on January 9, 2026, reaching allowance in under six months, and that the allowed claims address how issuers and shareholders can verify ownership and dividend entitlement when settlement discrepancies obscure the true share count.

Earlier in July, Datavault AI announced a proposed strategic partnership with Patriot Strategic Metals to jointly develop the Strategic Materials Acquisition Platform. The platform is designed to support the financing, tokenization, settlement, and lifecycle management of strategic mineral assets. CEO Nathaniel Bradley said the partnership brings together physical strategic assets and Datavault AI’s “institutional grade cyber secure digital infrastructure,” while combining PSM’s critical minerals platform with Datavault AI’s patented RWA technology.

Datavault AI Inc. (NASDAQ:DVLT) owns and operates data management platforms with high computing capabilities in North America, Asia Pacific, Europe, and internationally.

READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term. 

Disclosure: None. Follow Insider Monkey on Google News.